Michael Barbella, Managing Editor02.21.24
The U.S. Patent and Trademark Office has issued ENDRA Life Sciences Inc. a new patent titled, “Thermoacoustic Probe.”
U.S. Patent No. 11828727 (the '727 patent) relates to a thermoacoustic probe design with an optical transducer and an integrated wedge, which helps to minimize unwanted signals and optimizes radiofrequency signals to the targeted regions of interest. The '727 patent builds upon U.S. Patent No. 11730374, and is the second of two structural embodiments ENDRA is patenting to further protect its core technology.
“We are pleased with our continued IP momentum as TAEUS’ De Novo request advances through regulatory review. This 39 th U.S. patent bolsters our thermoacoustic technology in areas of high unmet clinical need,” ENDRA Chairman/CEO Francois Michelon stated. “With a total of 71 patents granted worldwide, ENDRA possesses robust IP protection for its novel TAEUS’ technology in key global markets.”
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a technology that characterizes tissue like magnetic resonance imaging (MRI), but at 1/50 th the cost and at the point of patient care. TAEUS is designed to work in concert with more than 700,000 ultrasound systems in use globally today. TAEUS is initially focused on measuring liver fat as a means to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects more than 2 billion people worldwide, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including tissue temperature visualization during energy-based surgical procedures.
U.S. Patent No. 11828727 (the '727 patent) relates to a thermoacoustic probe design with an optical transducer and an integrated wedge, which helps to minimize unwanted signals and optimizes radiofrequency signals to the targeted regions of interest. The '727 patent builds upon U.S. Patent No. 11730374, and is the second of two structural embodiments ENDRA is patenting to further protect its core technology.
“We are pleased with our continued IP momentum as TAEUS’ De Novo request advances through regulatory review. This 39 th U.S. patent bolsters our thermoacoustic technology in areas of high unmet clinical need,” ENDRA Chairman/CEO Francois Michelon stated. “With a total of 71 patents granted worldwide, ENDRA possesses robust IP protection for its novel TAEUS’ technology in key global markets.”
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a technology that characterizes tissue like magnetic resonance imaging (MRI), but at 1/50 th the cost and at the point of patient care. TAEUS is designed to work in concert with more than 700,000 ultrasound systems in use globally today. TAEUS is initially focused on measuring liver fat as a means to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects more than 2 billion people worldwide, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including tissue temperature visualization during energy-based surgical procedures.